Logo image of STOK

STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

USA - NASDAQ:STOK - US86150R1077 - Common Stock

24.14 USD
+1.19 (+5.19%)
Last: 9/26/2025, 8:00:00 PM
24.14 USD
0 (0%)
After Hours: 9/26/2025, 8:00:00 PM
Fundamental Rating

5

Taking everything into account, STOK scores 5 out of 10 in our fundamental rating. STOK was compared to 538 industry peers in the Biotechnology industry. STOK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. STOK has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year STOK was profitable.
STOK had a positive operating cash flow in the past year.
In the past 5 years STOK always reported negative net income.
In the past 5 years STOK always reported negative operating cash flow.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

STOK has a Return On Assets of 13.65%. This is amongst the best in the industry. STOK outperforms 95.17% of its industry peers.
STOK has a Return On Equity of 15.67%. This is amongst the best in the industry. STOK outperforms 94.80% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.20%, STOK belongs to the top of the industry, outperforming 93.68% of the companies in the same industry.
Industry RankSector Rank
ROA 13.65%
ROE 15.67%
ROIC 9.2%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

Looking at the Profit Margin, with a value of 26.26%, STOK belongs to the top of the industry, outperforming 95.91% of the companies in the same industry.
STOK has a better Operating Margin (20.15%) than 94.61% of its industry peers.
Industry RankSector Rank
OM 20.15%
PM (TTM) 26.26%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so STOK is destroying value.
STOK has more shares outstanding than it did 1 year ago.
STOK has more shares outstanding than it did 5 years ago.
STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 15.35 indicates that STOK is not in any danger for bankruptcy at the moment.
STOK has a Altman-Z score of 15.35. This is amongst the best in the industry. STOK outperforms 89.59% of its industry peers.
STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.35
ROIC/WACC0.93
WACC9.9%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 6.98 indicates that STOK has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.98, STOK is in the better half of the industry, outperforming 68.96% of the companies in the same industry.
A Quick Ratio of 6.98 indicates that STOK has no problem at all paying its short term obligations.
STOK has a better Quick ratio (6.98) than 69.33% of its industry peers.
Industry RankSector Rank
Current Ratio 6.98
Quick Ratio 6.98
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

STOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 142.58%, which is quite impressive.
The Revenue has grown by 1218.65% in the past year. This is a very strong growth!
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%

3.2 Future

The Earnings Per Share is expected to grow by 16.02% on average over the next years. This is quite good.
Based on estimates for the next years, STOK will show a very strong growth in Revenue. The Revenue will grow by 68.28% on average per year.
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.56%
EPS Next 5Y16.02%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

STOK is valuated quite expensively with a Price/Earnings ratio of 25.96.
Based on the Price/Earnings ratio, STOK is valued cheaply inside the industry as 93.87% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.32. STOK is around the same levels.
STOK is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 25.96
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of STOK indicates a rather cheap valuation: STOK is cheaper than 93.49% of the companies listed in the same industry.
STOK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. STOK is cheaper than 94.80% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.63
EV/EBITDA 20.43
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as STOK's earnings are expected to decrease with -16.56% in the coming years.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y-30.95%
EPS Next 3Y-16.56%

More info and screens

0

5. Dividend

5.1 Amount

STOK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STOKE THERAPEUTICS INC

NASDAQ:STOK (9/26/2025, 8:00:00 PM)

After market: 24.14 0 (0%)

24.14

+1.19 (+5.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-03 2025-11-03
Inst Owners118.79%
Inst Owner Change3.1%
Ins Owners4.3%
Ins Owner Change-18.03%
Market Cap1.32B
Analysts84.71
Price Target24.71 (2.36%)
Short Float %20.52%
Short Ratio12.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)291.04%
Min EPS beat(2)23.41%
Max EPS beat(2)558.67%
EPS beat(4)4
Avg EPS beat(4)165.54%
Min EPS beat(4)13.51%
Max EPS beat(4)558.67%
EPS beat(8)8
Avg EPS beat(8)88.85%
EPS beat(12)11
Avg EPS beat(12)62.04%
EPS beat(16)12
Avg EPS beat(16)29.4%
Revenue beat(2)2
Avg Revenue beat(2)863.06%
Min Revenue beat(2)52.02%
Max Revenue beat(2)1674.1%
Revenue beat(4)4
Avg Revenue beat(4)546.83%
Min Revenue beat(4)43.23%
Max Revenue beat(4)1674.1%
Revenue beat(8)7
Avg Revenue beat(8)280.95%
Revenue beat(12)10
Avg Revenue beat(12)183.53%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.31%
PT rev (3m)8.26%
EPS NQ rev (1m)3.85%
EPS NQ rev (3m)0.04%
EPS NY rev (1m)-2.84%
EPS NY rev (3m)117.65%
Revenue NQ rev (1m)-13.89%
Revenue NQ rev (3m)-29.68%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)7.87%
Valuation
Industry RankSector Rank
PE 25.96
Fwd PE N/A
P/S 6.62
P/FCF 21.63
P/OCF 21.48
P/B 3.95
P/tB 3.95
EV/EBITDA 20.43
EPS(TTM)0.93
EY3.85%
EPS(NY)-2.88
Fwd EYN/A
FCF(TTM)1.12
FCFY4.62%
OCF(TTM)1.12
OCFY4.66%
SpS3.65
BVpS6.11
TBVpS6.11
PEG (NY)0.22
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.65%
ROE 15.67%
ROCE 11.65%
ROIC 9.2%
ROICexc 32.43%
ROICexgc 32.43%
OM 20.15%
PM (TTM) 26.26%
GM N/A
FCFM 30.59%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 22.67%
Cap/Sales 0.23%
Interest Coverage 250
Cash Conversion 145.71%
Profit Quality 116.5%
Current Ratio 6.98
Quick Ratio 6.98
Altman-Z 15.35
F-Score8
WACC9.9%
ROIC/WACC0.93
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)142.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y117.64%
EPS Next 2Y-30.95%
EPS Next 3Y-16.56%
EPS Next 5Y16.02%
Revenue 1Y (TTM)1218.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.01%
Revenue Next Year914.78%
Revenue Next 2Y31.67%
Revenue Next 3Y35.53%
Revenue Next 5Y68.28%
EBIT growth 1Y135.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.74%
EBIT Next 3Y-11.06%
EBIT Next 5Y21.61%
FCF growth 1Y167.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y170.32%
OCF growth 3YN/A
OCF growth 5YN/A